Stream Biomedical

Stream Biomedical is pioneering a regenerative therapeutic approach for acute brain injury and neurodegeneration with its lead biologic candidate, LG3. The therapy is designed to activate the brain's intrinsic repair systems by targeting multiple pathways involved in vascular integrity, inflammation, and neuronal recovery. Founded in 2018 and based in San Diego, the company is in the preclinical stage, with data supporting activity across multiple disease models. Its strategy addresses a significant unmet medical need across major neurological indications with a single, potentially disease-modifying agent.

LG3 biologic platform targeting neurovascular repair; a multi-mechanism approach designed to protect brain cells, reduce inflammation, repair the blood-brain barrier, and reactivate endogenous neurorepair pathways.

Competition includes large pharma with approved amyloid-targeting antibodies in Alzheimer's and numerous companies pursuing neuroprotection/repair in stroke and TBI. Stream's differentiation lies in its specific focus on the LG3 fragment and its multi-faceted approach to neurovascular repair.